High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Year: 2016
Type: article
Study design: Observational Study
Abstract: CLL. We examined the CLL cells from 1568 patients, which we randomly assigned to a training or validation set of 797 or 771 cases, respectively. Using recursive partitioning, we defined a threshold for ROR1 surface expression that could segregate samples of the training set into ROR1-Hi vs ROR1-Lo subgroups that differed significantly in their median treatment-free survival (TFS). Using this threshold, we found that ROR1-Hi cases had a significantly shorter median TFS and overall survival than ROR1-Lo cases in the validation set. These data demonstrate that expression of ROR1 may promote leukemia-cell activation and survival and enhance disease progression in patients with CLL.
Source: Blood
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, University of California San Diego, Moores Cancer Center, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, The University of Texas MD Anderson Cancer Center, Northwell Health, Hofstra University, Mayo Clinic, The Ohio State University, Queen Mary University of London, Barts Cancer Institute, Rady Children's Hospital-San Diego
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2547412310